These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19412697)

  • 1. [Third generation beta-blockers: current state of research on vasodilating beta-blockers].
    Ladage D; Reidenbach C; Lichtenthal A; Schwinger R; Brixius K
    Wien Med Wochenschr; 2009; 159(7-8):211-8. PubMed ID: 19412697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
    Toblli J; Cao G; Rivas C; Munoz M; Giani J; Dominici F; Angerosa M
    J Hypertens; 2010 May; 28(5):1007-19. PubMed ID: 20411618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers.
    Schmidt AC; Flick B; Jahn E; Bramlage P
    Vasc Health Risk Manag; 2008; 4(4):909-15. PubMed ID: 19066009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nebivolol on human platelet aggregation.
    Falciani M; Rinaldi B; D'Agostino B; Mazzeo F; Rossi S; Nobili B; Rossi F; Filippelli A
    J Cardiovasc Pharmacol; 2001 Dec; 38(6):922-9. PubMed ID: 11707696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.